Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) has emerged as a notable player in the biopharmaceutical sector, transitioning from a development-stage company to one with commercial revenue, driven by the FDA-approved targeted immunotherapy LYMPHIR. The company’s strategic focus on first-in-class critical care products with significant unmet medical needs positions it for potential growth, with multiple catalysts on the horizon.
LYMPHIR, approved by the U.S. Food and Drug Administration in August 2024, is a targeted immunotherapy for adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. The commercial launch in December 2025 has already generated $5.6 million in net product revenue during the first six months of fiscal 2026, with gross margins of approximately 80%. This revenue stream marks a significant milestone for Citius, providing a commercial-stage exposure to the oncology market.
The company’s oncology subsidiary, Citius Oncology, Inc. (NASDAQ: CTOR), has achieved broad payer coverage, with nearly 100% of covered commercial lives and 83% of targeted accounts having formulary inclusion or under active review. Additionally, Citius announced an initial shipment of LYMPHIR to Europe in April 2026, signaling international expansion. Repeat orders from initial accounts suggest growing physician engagement and market penetration.
Beyond the approved CTCL indication, Citius is exploring LYMPHIR’s potential in other oncology settings. Investigator-initiated studies have evaluated LYMPHIR in combination with pembrolizumab for recurrent or refractory gynecologic cancers and with CD19-directed CAR-T therapy for high-risk relapsed or refractory diffuse large B-cell lymphoma. Positive topline results from both Phase 1 studies were reported in fiscal 2026, potentially expanding the drug’s addressable market.
Citius’s late-stage pipeline includes Mino-Lok, an antibiotic lock solution designed to salvage central venous catheters in patients with catheter-related bloodstream infections (CRBSIs) and central line-associated bloodstream infections (CLABSIs). These infections are particularly serious in cancer and hemodialysis patients, and there are currently no FDA-approved therapies specifically indicated to salvage infected catheters. Mino-Lok met its primary and secondary endpoints in a pivotal Phase 3 superiority trial and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations. Following a Type C meeting with the FDA, the company received guidance outlining a pathway to support a future New Drug Application submission. Investor materials estimate worldwide sales potential of approximately $1.8 billion.
Another pipeline candidate, Halo-Lido, is a proprietary topical formulation combining halobetasol and lidocaine for the symptomatic treatment of hemorrhoids. With an estimated 10 million people in the U.S. reporting hemorrhoid symptoms annually, and no FDA-approved prescription products specifically for hemorrhoids, Halo-Lido could become the first such product if approved. The company completed a Phase 2b study in 2023 and has engaged with the FDA on next steps.
Citius is also developing a stem cell platform based on induced pluripotent stem cell-derived mesenchymal stem cells (i-MSCs) for acute respiratory distress syndrome (ARDS), including lung injury associated with sepsis. Interim results from a proof-of-concept sheep model showed improvements in oxygenation, systemic shock, pulmonary vascular injury, and bacterial clearance compared with controls. These data will inform future human clinical trials.
The company’s leadership team, including CEO Leonard Mazur with five decades of pharmaceutical experience, brings extensive development, commercialization, and business development expertise. With LYMPHIR generating revenue and additional programs progressing, Citius is positioned around multiple potential catalysts. For more information, visit Citius Pharma.
